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Background: Use of food supplements-containing phytoestrogens among postmenopausal women is rapidly
increasing. Although phytoestrogens are often perceived as safe, evidence for overall positive risk-benefit profile
is still inconclusive. The chance to buy them by user’s initiative does not facilitate surveys on their prevalence
and pattern of use. The aim of this study was to describe the pattern of use and self-reported positive and
negative perceptions of phytoestrogens in post-menopausa.
Methods: A questionnaire was administered to women who were buying food supplements containing phytoestrogens
in 22 pharmacies located in the Bologna area (400,000 inhabitants). Questionnaire was structured into 3 sections:
(a) socio-demographic information, (b) pattern of use, (c) positive and negative perceptions.
Results: Data on 190 peri- and post-menopausal women (aged 38–77) were collected. Women stated to use
phytoestrogens to reduce hot flushes (79%), insomnia (15%), mood disturbances (14%) and prevent osteoporosis
(15%). The majority (59%) took phytoestrogens routinely, whereas 28% in 3-month cycles. Among positive perceptions
between short- and long-term users, a not negligible difference was reported for relief of hot-flushes (68% in short-term
vs. 81% in long-term users; p = 0.04). Negative perceptions were reported more frequently in the long-term group, and
this difference was statistically significant for edema (6% in short-term vs. 17% in long-term users; p = 0.04), but not for
other effects: e.g., swelling sensation (10% vs. 21%; p = 0.09), somnolence (7% vs. 10% p = 0.62), fatigue (4% vs.11%
p = 0.15).
Conclusions: In the Bologna area, the pattern of use of phytoestrogens for menopausal symptoms is heterogeneous,
and women overall find these substances to be beneficial, especially for relief of hot-flushes. Other positive perceptions
decreased with long-term use. Negative perceptions, especially estrogen-like effects, seem to be infrequent and increase
with long-term therapy. Physicians should pay attention to effects perceived by post-menopausal women and routinely
monitor the use of phytoestrogens, in order to recognize possible adverse effects and actual benefits.
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The peri- and post-menopausal years are typically charac-
terized by vasomotor symptoms, such as hot flushes and
night sweats, due to the reduction of circulating estrogen
levels. Therefore, the Hormone Replacement Therapy
(HRT) approach, by replacing endogenous estrogens with
exogenous hormones, was primarily advocated to limit* Correspondence: elisabetta.poluzzi@unibo.it
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unless otherwise stated.both short and long-term consequences due to decreased
estrogen level. In fact, several Randomized Control
Trials recruiting postmenopausal women demonstrated
the reduction of vasomotor symptoms in HRT short-term
users [1].
The HRT was considered the most common choice
for the treatment of menopausal symptoms until the
publication of Women Health Initiative (WHI) Trial, in
2002. This trial reported that the risk of HRT treatment
in the long-term use outweighed the benefits, due to theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Girardi et al. BMC Complementary and Alternative Medicine 2014, 14:262 Page 2 of 5
http://www.biomedcentral.com/1472-6882/14/262increased risk of breast cancer, stroke, thromboembol-
ism, gallbladder disease and dementia [2]. Moreover, re-
sults from the WHI follow-up study did not support use
of HRT for chronic disease prevention, although it re-
mains a reasonable option for the management of mod-
erate to severe menopausal symptoms [3].
Although the HRT is still considered the most effect-
ive treatment for unacceptable vasomotor symptoms,
their prescription rates drastically decreased after the
publication of WHI results [4] and after the new recom-
mendations published by Regulatory Agencies [5,6]. The
use of alternative therapies for menopausal symptoms
became very popular among women; in particular, ther-
apies based on phytoestrogens represent the most com-
mon alternative to HRT [7].
Phytoestrogens are non-steroidal compounds derived
both from plants and from the in vivo metabolism of
precursors contained in several plants traditionally usedTable 1 Socio-demographic and clinical characteristics of resp
Features Total Short-term users
(≤1 year)





Italian 180 (97) 72 (96)
Not Italian 6 (3) 3 (4)
Concomitant Disease
High blood pressure 45 (24) 16 (21)
Diabetes 4 (2) 1 (1)
Osteoporosis 24 (13) 8 (11)
Heart disorders 18 (9) 5 (7)
Circulatory disorders
(es. thrombosis)
27 (14) 11 (15)
High levels of Cholesterol 87 (46) 34 (44)
Liver diseases 7 (4) 4 (5)
Hepatic lithiasis (calculus) 17 (9) 6 (8)
Obesity 18 (9) 6 (8)
Concomitant Diagnosis
Fracture of the thigh-bone or spine 3 (2) 2 (3)
Breast cancer 8 (4) 1 (1)
Uterine cancer 4 (2) 3 (4)
Ovarian cancer 1 (1) 0 (0)
Family history of breast
cancer
36 (80) 4 (5)
Already in the menopausal
period
166 (87) 60 (80)
aMissing information on therapy duration in 2 questionnaires; bTwo-sample T-test w
with 5 obs. or less, Two-Sample test of proportions was used for other variables; ***p-vas food. These secondary metabolites induce biological
responses and can mimic or modulate the actions of en-
dogenous estrogens, usually by binding to Estrogen Re-
ceptors [8]. The most common types of phytoestrogens
are coumestans, lignans and isoflavones.
The potential benefits of therapies based on phytoes-
trogens have been investigated during the last two de-
cades with escalating interest, as demonstrated by the
increasing number of pre-clinical and clinical trials since
the 90s [1]. A number of Randomized Controlled Trials
have been conducted in menopausal women to verify
the efficacy of phytoestrogen in improving menopausal
symptoms [7]; however, there is still a lack of good infor-
mation on the risk and benefits of this approach.
The classification of the phytoestrogen products as
food supplements does not facilitate surveys on their
prevalence and pattern of use by collecting prescription






N (%) 86a (100) pb N (%) 27a (100)
58 0.00*** 56
38-74 45-77
85 (99) 0.22 25 (93)
1 (1) 0.34 2 (7)
21 (24) 0.83 8 (30)
1 (1) insufficient observations 2 (7)
14 (16) 0.75 2 (7)
9 (10) 0.58 4 (15)
13 (15) 1.00 3 (11)
43 (50) 0.60 11 (41)
3 (3) 0.71 0 (0)
8 (9) 0.95 3 (11)
8 (9) 0.95 4 (15)
1 (1) 0.60 0 (0)
6 (7) 0.12 1 (4)
1 (1) 0.34 0 (0)
1 (1) insufficient observations 0 (0)
16 (19) 0.02** 6 (22)
84 (98) 0.00*** 21 (78)
as used to compare average age, Exact Fisher test was used in case of variables
alue < 0.01; **p-value < 0.05.
Figure 1 Period of administration of phytoestrogens. Missing data on duration of therapy in 2 questionnaires.
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direct dispensation to the patient by the pharmacists
represents the most suitable observational point to col-
lect data on this topic.
The purpose of this study was to describe the pattern of
use of phytoestrogens in peri- and post-menopausal women
and to report their positive and negative perceptions.
Methods
A questionnaire-based survey was conducted in 22 Phar-
macies located in the Bologna area (400,000 of inhabi-
tants) and enrolled all women who were buying food
supplements containing phytoestrogens between April
and September 2012. The questionnaire was distributed
by the pharmacist, making sure to avoid influence on
the free choice of the product and answers to relevant
questions. After signing informed consent, women au-
tonomously filled-in the questionnaire, with the pharma-
cists assistance in case clarifications were needed.
The questionnaire was anonymous and structured in
three different sections: (1) socio-demographic informationFigure 2 Benefits expected by women using phytoestrogens.(e.g. date of birth, nationality, work position); (2) pattern of
use (e.g. duration and frequency of therapy); (3) positive
and negative perceptions. At the end of the questionnaire,
the name of the product was recorded (Additional file 1:
Questionnaire).
The study obtained the approval from the Ethic Com-
mittee of the Local Health Authority of Bologna.
All collected data were analysed by using descriptive
statistics. Subjects were grouped according to treatment
duration in short-term users (≤1 yr of treatment) and
long-term users (>1 yr of treatment). Differences in
demographic and clinical characteristics, as well in posi-
tive and negative perceptions between these two groups
were assessed by appropriate statistical tests (as ac-
knowledged in the relevant tables; p <0.05).
Results
We collected 190 questionnaires from 38- to 77-year old
women. The 88% of the cohort declared to be in the
postmenopausal period (41% within the previous 4 years);
35% of participants reported high cholesterol levels, 18%
Table 2 Differences in positive perceptions between short- and long-term users
Positive Perceptions All users N (%) Short-term users N (%) Long-term users N (%) Chi square p value
163a (100) 75b (100) 86b (100)
Reduction of hot flushes 121 (74) 51 (68) 70 (81) 4.34 0.04
Well-being increase 84 (52) 44 (59) 40 (47) 0.41 0.52
Mood increase 79 (48) 38 (51) 41 (48) 0.02 0.89
Palpitation 60 (37) 28 (37) 32 (37) 0.01 0.92
aExcluding new users; bMissing data on duration of therapy in 2 questionnaires.
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breast cancer diagnosis before starting phytoestrogens
(Table 1).
In 45.3% of cases, women have been taking phytoes-
trogens for more than 1 year (long-term users), 39.5%
for less than 1 year (short-term users) and the 14.2% de-
clared to be new user (i.e., they resorted to the product
for the first time) (Figure 1). No differences in demo-
graphic and clinical characteristics were found between
short- and long-term users, except for time-related vari-
ables (age and menopausal status).
Among long-term users, 60 specified the duration of
the therapy: 40 for less than 5 years, 17 for 6–10 years
and 3 for more than 11 years. Fifty-two percent of
women were advised to take phytoestrogens by special-
ist (gynecologist or endocrinologist), 19% by pharma-
cist, and 9% by general practitioner.
Twenty-five different products containing phytoestro-
gens were considered in the survey; all products contained
isoflavones (dosage ranged 40 - 80 mg), mainly derived
from soy (56%) and Trifolium prantense (28%).
Participants used phytoestrogens with different goals, in
particular to reduce hot flushes (79%), insomnia (15%),
mood disturbances (14%), and to prevent osteoporosis
(15%; Figure 2). Concerning the pattern of use, the major-
ity (59%) took their food supplement routinely, every day,
whereas 28% in cycles (especially 3-month-cycles).
Seventy-four percent of the participants perceived a
reduction of hot flushes with the phytoestrogen assump-
tion; positive perceptions included also increased well-
being (52%), mood improvement (48%) and reduction of
palpitations (37%). Among negative perceptions, 15% of
women reported a swelling sensation, 11% edema occur-
rence, 8% somnolence and 7% fatigue.Table 3 Differences in negative perceptions between short-te
Negative Perceptions All users N (%) Short-term users N
163a (100) 67b (100)
Swelling sensation 24 (15) 7 (10)
Edema 18 (11) 4 (6)
Somnolence 13 (8) 5 (7)
Fatigue 12 (7) 3 (4)
aExcluding new users; bMissing data on duration of therapy or negative perceptionsThe comparison in terms of positive perceptions be-
tween short-term and long-term users showed that: re-
duction of hot flushes for long-term users was greater
(81% vs. 68%, p = 0.04), whereas no statistically signifi-
cant difference was found in reduction of palpitation
(37% vs. 37%, p = 0.92) and mood improvement (51% vs.
48%, p = 0.89; Table 2). Negative perceptions were re-
ported more frequently among long-term users; differ-
ences were statistically significant for edema (6% in
short-term vs. 17% in long-term users; p = 0.04), but not
for other effects: swelling sensation (10% vs. 21%; p =
0.09), somnolence (7% vs. 10% p = 0.62), fatigue (4%
vs.11% p = 0.15; Table 3).
Discussion
This study provides for the first time Italian data about
the pattern of use of phytoestrogens for postmenopausal
symptoms and relevant perception of effects by users:
the majority of women took this food supplement every
day for more than 1 year, especially to reduce vasomotor
symptoms. Overall, women found these substances to be
beneficial, especially for relief of hot-flushes; this effect
seemed to increase with long-term use, although these
findings could partially be ascribed to physiological re-
duction of vasomotor symptoms during the menopausal
course. On the contrary, other positive perceptions (either
physical and psychological) appeared to decrease with
long-term use. Negative perceptions (e.g., swelling and
edema) seem to be infrequent, increase with long-term
therapy and, notably, to be estrogen-related. It is well
known that phytoestrogens structurally resemble estradiol
and because of this similarity, they can bind human Estro-
gen Receptors and mimic the actions of endogenous es-
trogens [9]. Healthcare professionals should be activelyrm and long-term users
(%) Long-term users N (%) Chi square p value
82b (100)
17 (21) 2.89 0.09
14 (17) 4.38 0.04
8 (10) 0.24 0.62
9 (11) 2.10 0.15
in 12 questionnaires.
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gens. In particular, both physicians and pharmacists
should critically consider if and when therapy is appropri-
ate. Moreover they have a crucial role in recognizing pos-
sible clinical consequences, either benefits and adverse
effects, of phytoestrogens also by paying attention to
women perceptions.
This investigation has different limitations, including
population enrollment, as women were involved on a
voluntarily basis and the study was limited to the Bol-
ogna area. In addition, the qualitative and quantitative
composition of the products were heterogeneous and
not exactly titrated, therefore reported perceptions could
be also affected by different doses and ingredients of
products. Our results were based on women percep-
tions, that cannot be considered a hard endpoint.
Despite limitations, this approach was capable of de-
tecting some expected estrogen-like effects by using
proxy measures (e.g., swelling and edema), and it is feas-
ible and replicable as a possible strategy when formal
studies are not easily applicable, as in the case of food
supplements. Furthermore, this strategy is also able to
describe women’s attitude, which is a direct consequence
of the source of the suggestion to take phytoestrogens.Conclusions
Studies conducted so far did not fill the gap of know-
ledge to support recommendations about appropriate
use of phytoestrogen. Future efforts should be addressed
towards clinical trials with adequate sample size and de-
signed to compare head-to-head different concentration
of phytoestrogens against active comparator, namely hor-
mone therapy or any other standard therapy for a given
disorder.
Moreover, our survey suggests that it is possible to ob-
tain data about extent and pattern of use of phytoestro-
gens, with the collaboration of pharmacists. Women’s
perceptions should be considered as an important end-
point while investigating the use of food supplements,
especially because the conduction of formal studies is
challenging in this category of products. Our question-
naire could be a useful tool for this purpose and should
be adopted in additional cohorts of women to verify our
results on a more extended area.Additional file
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